PEGylation Reagents for Drug Delivery
Gelest, a manufacturer and provider of silane, silicone, and metal-organic compounds, released a range of dual-function poly(ethylene glycol) (PEG) reagents that enable new approaches to PEGylation for bioconjugates.
Gelest, a manufacturer and provider of silane, silicone, and metal-organic compounds, released a range of dual-function poly(ethylene glycol) (PEG) reagents that enable new approaches to PEGylation for bioconjugates, reduction of surface biofouling, and formation of polymerizeable vesicles for drug transport.
These materials are heterobifunctional with an amine at one terminus, and a choice of two different species at the other terminus. One species can undergo radical reactions, and the second species can undergo hydrolytic condensation.
In addition to reacting directly with appropriate functionality of drug or protein substrates, these materials have the potential to undergo polymerization, and to form polymerizeable vesicles, stabilizing PEGylated drugs or acting as co-monomers for microencapsulated drug delivery. The polymerization can proceed by either free-radical organic polymerization or hydrolysis-condensation siloxane polymerization.
Source: Gelest
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 31st 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 31st 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.
